159 related articles for article (PubMed ID: 4361727)
21. Poliovirus Sabin type 1 neutralization epitopes recognized by immunoglobulin A monoclonal antibodies.
Fiore L; Ridolfi B; Genovese D; Buttinelli G; Lucioli S; Lahm A; Ruggeri FM
J Virol; 1997 Sep; 71(9):6905-12. PubMed ID: 9261417
[TBL] [Abstract][Full Text] [Related]
22. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.
Bockstal V; Tiemessen MM; Achterberg R; Van Wordragen C; Knaapen AM; Serroyen J; Marissen WE; Schuitemaker H; Zahn R
Vaccine; 2018 Nov; 36(46):6979-6987. PubMed ID: 30314910
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the immune response of the rabbit to virulent and attenuated strains of type 1 poliovirus.
Gaudin OG; Viac J; Thouvenot D; Sohier R
Bull World Health Organ; 1974; 50(6):479-5. PubMed ID: 4376464
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity of a supplemental dose of oral versus inactivated poliovirus vaccine.
Moriniere BJ; van Loon FP; Rhodes PH; Klein-Zabban ML; Frank-Senat B; Herrington JE; Pallansch MA; Patriarca PA
Lancet; 1993 Jun; 341(8860):1545-50. PubMed ID: 8099637
[TBL] [Abstract][Full Text] [Related]
25. Differences in Antigenic Structure of Inactivated Polio Vaccines Made From Sabin Live-Attenuated and Wild-Type Poliovirus Strains: Impact on Vaccine Potency Assays.
Crawt L; Atkinson E; Tedcastle A; Pegg E; ; Minor P; Cooper G; Rigsby P; Martin J
J Infect Dis; 2020 Feb; 221(4):544-552. PubMed ID: 30788503
[TBL] [Abstract][Full Text] [Related]
26. Infection induced by oral administration of attenuated poliovirus to persons possessing homotypic antibody.
HORSTMANN DM; PAUL JR; MELNICK JL; DEUTSCH JV
J Exp Med; 1957 Jul; 106(1):159-77. PubMed ID: 13439122
[TBL] [Abstract][Full Text] [Related]
27. Immunogenicity in monkeys of two polio type 3 seed viruses (SO + 2 and SOR + 1) presently used for production of oral polio vaccine.
Sokhey J; Sharma B; Singh H
J Commun Dis; 1989 Dec; 21(4):301-8. PubMed ID: 2561635
[TBL] [Abstract][Full Text] [Related]
28. A recombinant virus between the Sabin 1 and Sabin 3 vaccine strains of poliovirus as a possible candidate for a new type 3 poliovirus live vaccine strain.
Kohara M; Abe S; Komatsu T; Tago K; Arita M; Nomoto A
J Virol; 1988 Aug; 62(8):2828-35. PubMed ID: 2839704
[TBL] [Abstract][Full Text] [Related]
29. Vaccinology of poliomyelitis.
Salk D; Salk J
Vaccine; 1984 Mar; 2(1):59-74. PubMed ID: 6099644
[TBL] [Abstract][Full Text] [Related]
30. Antibody response and viral excretion after live polio vaccine or a combined schedule of live and inactivated polio vaccines.
Ramsay ME; Begg NT; Gandhi J; Brown D
Pediatr Infect Dis J; 1994 Dec; 13(12):1117-21. PubMed ID: 7892081
[TBL] [Abstract][Full Text] [Related]
31. Decision analysis in planning for a polio outbreak in the United States.
Jenkins PC; Modlin JF
Pediatrics; 2006 Aug; 118(2):611-8. PubMed ID: 16882814
[TBL] [Abstract][Full Text] [Related]
32. Progress with inactivated poliovirus vaccines derived from the Sabin strains.
Doi Y; Abe S; Yamamoto H; Horie H; Ohyama H; Satoh K; Tano Y; Ota Y; Miyazawa M; Wakabayashi K; Hashizume S
Dev Biol (Basel); 2001; 105():163-9. PubMed ID: 11763324
[TBL] [Abstract][Full Text] [Related]
33. Interrupting the transmission of wild polioviruses with vaccines: immunological considerations.
Ghendon Y; Robertson SE
Bull World Health Organ; 1994; 72(6):973-83. PubMed ID: 7867144
[TBL] [Abstract][Full Text] [Related]
34. Effect of prior immunity on the shedding of virulent revertant virus in feces after oral immunization with live attenuated poliovirus vaccines.
Ogra PL; Faden HS; Abraham R; Duffy LC; Sun M; Minor PD
J Infect Dis; 1991 Jul; 164(1):191-4. PubMed ID: 1647422
[TBL] [Abstract][Full Text] [Related]
35. [Studies on safety tests of inactivated poliomyelitis vaccines. V. Pathomorphological changes in the CNS of rhesus monkeys (Macaca rhesus) and long-tailed monkeys (Cercopithecus aethiops) following intracerebral and intralumbar inoculation with inactivated poliovirus types I, II, and 3].
Unterharnscheidt F; Günther O; Hövel H; Burde K; Heber L
Zentralbl Bakteriol Orig; 1966 Jun; 200(2):150-66. PubMed ID: 4296871
[No Abstract] [Full Text] [Related]
36. Evaluation of immunogenicity and protective properties of inactivated poliovirus vaccines: a new surrogate method for predicting vaccine efficacy.
Dragunsky EM; Ivanov AP; Wells VR; Ivshina AV; Rezapkin GV; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
J Infect Dis; 2004 Oct; 190(8):1404-12. PubMed ID: 15378432
[TBL] [Abstract][Full Text] [Related]
37. Further development of a new transgenic mouse test for the evaluation of the immunogenicity and protective properties of inactivated poliovirus vaccine.
Dragunsky EM; Ivanov AP; Abe S; Potapova SG; Enterline JC; Hashizume S; Chumakov KM
J Infect Dis; 2006 Sep; 194(6):804-7. PubMed ID: 16941347
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a recombinant type 3/type 2 poliovirus isolated from a healthy vaccinee and containing a chimeric capsid protein VP1.
Blomqvist S; Bruu AL; Stenvik M; Hovi T
J Gen Virol; 2003 Mar; 84(Pt 3):573-580. PubMed ID: 12604808
[TBL] [Abstract][Full Text] [Related]
39. Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis.
Viktorova EG; Khattar SK; Kouiavskaia D; Laassri M; Zagorodnyaya T; Dragunsky E; Samal S; Chumakov K; Belov GA
J Virol; 2018 Sep; 92(17):. PubMed ID: 29925653
[TBL] [Abstract][Full Text] [Related]
40. Antigenic modification of attenuated Sabin type 1 poliovirus by in vitro passages at supraoptimal temperatures.
Crainic R; Blondel B; Candréa A; Dufraisse G; Horaud F
Dev Biol Stand; 1985; 60():343-7. PubMed ID: 2995173
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
